This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Efficacy of a medical food in mild Alzheimer’s disease: A randomized, controlled trial


Scheltens, Philip, Kamphuis, Patrick J. G. H., Verhey, Frans R.J., Olde Rikkert, Marcel G. M., Wurtman, Richard J., Wilkinson, David, Twisk, Jos W.R., Kurz, Alexander


Alzheimer's & Dementia: The Journal Of The Alzheimer's Association, Volume: 6, No.: 1, Pages.: 1-10.e1

Year of Publication



Objective: To investigate the effect of a medical food on cognitive function in people with mild Alzheimer’s disease (AD).; Methods: A total of 225 drug-naïve AD patients participated in this randomized, double-blind controlled trial. Patients were randomized to active product, Souvenaid, or a control drink, taken once-daily for 12 weeks. Primary outcome measures were the delayed verbal recall task of the Wechsler Memory Scale-revised, and the 13-item modified Alzheimer’s Disease Assessment Scale-cognitive subscale at week 12.; Results: At 12 weeks, significant improvement in the delayed verbal recall task was noted in the active group compared with control (P = .021). Modified Alzheimer’s Disease Assessment Scale-cognitive subscale and other outcome scores (e.g., Clinician Interview Based Impression of Change plus Caregiver Input, 12-item Neuropsychiatric Inventory, Alzheimer’s disease Co-operative Study-Activities of Daily Living, Quality of Life in Alzheimer’s Disease) were unchanged. The control group neither deteriorated nor improved. Compliance was excellent (95%) and the product was well tolerated.; Conclusions: Supplementation with a medical food including phosphatide precursors and cofactors for 12 weeks improved memory (delayed verbal recall) in mild AD patients. This proof-of-concept study justifies further clinical trials.; 2010 The Alzheimer’s Association. All rights reserved.

Bibtex Citation

@article{Scheltens_2010, doi = {10.1016/j.jalz.2009.10.003}, url = {}, year = 2010, month = {jan}, publisher = {Elsevier {BV}}, volume = {6}, number = {1}, pages = {1--10.e1}, author = {Philip Scheltens and Patrick J.G.H. Kamphuis and Frans R.J. Verhey and Marcel G.M. Olde Rikkert and Richard J. Wurtman and David Wilkinson and Jos W.R. Twisk and Alexander Kurz}, title = {Efficacy of a medical food in mild Alzheimer{textquotesingle}s disease: A randomized, controlled trial}, journal = {Alzheimer{textquotesingle}s {&} Dementia} }


aged, aged, 80 and over, alzheimer disease, cognition disorders, complications, diet therapy, double-blind method, drug administration schedule, etiology, female, food, functional food, humans, male, memory, middle aged, neuropsychological tests, physiology, psychiatric status rating scales, souvenaid, therapy, time factors, treatment outcome

Countries of Study


Types of Dementia

Alzheimer’s Disease

Types of Study

Randomised Controlled Trial

Type of Outcomes

ADLs/IADLs, Behaviour, Cognition

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Herbal remedies, vitamins, dietary supplements